Supplementary Data from Antitumor Activity of BIBF 1120, a Triple Angiokinase Inhibitor, and Use of VEGFR2&lt;sup&gt;+&lt;/sup&gt;pTyr&lt;sup&gt;+&lt;/sup&gt; Peripheral Blood Leukocytes as a Pharmacodynamic Biomarker &lt;i&gt;In Vivo&lt;/i&gt;